The new drug, SOLAR, would offer longer-lasting injections instead of a daily pill.
Oak Cliff-based Prism Health North Texas is seeking patients in a clinical trial of the drug.
Here’s how Prism describes who is eligible:
SOLAR is a clinical trial for people living with HIV who are currently doing well on their current single tablet daily oral regimen and might be interested in helping researchers determine if it is safe and effective to switch to a completely injectable, investigational regimen given as two injections every two months. Individuals who have been living with HIV and have been undergoing treatment for at least six months, may qualify to participate in the trial.
Those who volunteer will be assigned at random to continue their current HIV medications (about 33% of participants) or switch to the investigational medications (about 67% of participants).
The FDA approved this combination of two long-acting drugs, cabotegravir and rilpivirine, for monthly injections, and this study tests its efficacy against that of the daily pill.
If it’s proven to be as effective or better, then everyone in both testing groups who completes the initial trial will be given the opportunity to continue the injections for two years as part of ongoing study.
Investigational medications and study-related tests will be provided at no cost, and participants will receive compensation for their time, effort and travel expenses.
Find more information about the clinical trial here.
